Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Oligodendroglioma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 45Radiotherapy 16Carboplatin 15Irinotecan 12Carmustine 12Bevacizumab 12Filgrastim 10Vincristine 9Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 9Procarbazine 7Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Erlotinib Hydrochloride 6temsirolimus 5sargramostim 5O(6)-benzylguanine 5Lomustine 5Flucytosine 5Etoposide 5Thiotepa 4Sirolimus 4Cyclophosphamide 4aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Sunitinib 3Radiotherapy, Intensity-Modulated 3Radiation 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oligodendroglioma × efaproxiral × Clear all
NCT00005855 2013-06-21

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡